Dalbavancin in Bone and Joint Infections: A Systematic Review
Pharmaceuticals · 15.07.2023 · 16 (7) · 1005
DOI: 10.3390/ph16071005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 15.07.2023. Verfasst von Sofia Lovatti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili di Brescia,…. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Approved for acute bacterial skin and skin structure infections, dalbavancin (DBV) has gradually acquired over the years a role as an off-label treatment for several infections caused by Gram-positive bacteria even in other anatomical sites. Osteoarticular (OA) infections are one of the most difficult-to-treat infections and, since the absence of recommendations, clinicians use different and heterogenic DBV dosing schedule regimens for the off-label treatment of osteomyelitis, spondylodiscitis, and septic arthritis. Our aim is to systematically review the current literature to describe DBV administration schedules and their outcome in OA infections.
Methods
According to the 2020 updated PRISMA guidelines, all peer-reviewed articles regarding the use of DBV in OA infections were included. We conducted a literature search on PubMed and Cochrane Controlled Trials.
Results
A total of 23 studies and 450 patients were included, prevalently male (144/195, 73.8%) and diabetic (53/163, 32.5%). Overall, 280 (280/388, 72.2%) osteomyelitis, 79 (79/388, 20.4%) spondylodiscitis, and 29 (29/388, 7.5%) septic arthritis were considered. Staphylococcus aureus (164/243, 67.5%) was the most common pathogen isolated. A previous treatment failure (45/96, 46.9%) was the main reason for a switch to a long-acting antibiotic. Most patients were successfully cured with DBV (318/401, 79.3%). A source control was performed in most patients with a favourable outcome (80.4%), while MRSA was prevalently isolated in people with an unfavourable outcome (57%). While a higher percentage of success was found in people who received three doses of DBV 1 week apart (92.3%), a higher rate of treatment failure was recorded in cases of when the DBV cycle was composed of less than two or more than four doses (27.8%).
Conclusions
DBV has shown to be effective as a treatment for OA infections. The most favourable outcome was found in patients receiving three doses of DBV and with an adequate surgical management prior to antibiotic treatment. Although a rigorous administration schedule does not exist, DBV is a viable treatment option in the management of OA infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
- Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
ORCID-Profile: Giorgio Tiecco, Eugenia Quiros-Roldan
Zitieren
APA
Lovatti, S., Tiecco, G., Mulé, A., Rossi, L., Sforza, A., Salvi, M., Signorini, L., Castelli, F., & Quiros-Roldan, E. (2023). Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharmaceuticals, 16(7), 1005. https://doi.org/10.3390/ph16071005
Vancouver
Lovatti S, Tiecco G, Mulé A, Rossi L, Sforza A, Salvi M, et al. Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharmaceuticals. 2023;16(7):1005. doi:10.3390/ph16071005
BibTeX
@article{Lovatti2023,
author = {Lovatti, Sofia and Tiecco, Giorgio and Mulé, Alice and Rossi, Luca and Sforza, Anita and Salvi, Martina and Signorini, Liana and Castelli, Francesco and Quiros-Roldan, Eugenia},
title = {Dalbavancin in Bone and Joint Infections: A Systematic Review},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {7},
pages = {1005},
doi = {10.3390/ph16071005}
}
EUVIMED